- Home
- ALV vs LEGN Comparison
ALV vs LEGN Comparison
Compare ALV & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALV | LEGN |
|---|---|---|
| Founded | 1953 | 2014 |
| Country | Sweden | United States |
| Employees | 65200 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALV | LEGN |
|---|---|---|
| Price | $102.14 | $18.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $137.10 | $63.08 |
| AVG Volume (30 Days) | 635.8K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.76 | $46.27 |
| Revenue Next Year | $3.52 | $28.77 |
| P/E Ratio | $13.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $75.49 | $16.24 |
| 52 Week High | $130.14 | $45.30 |
Technical Indicators
Market Signals| Indicator | ALV | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 21.71 | 44.37 |
| Support Level | N/A | $17.46 |
| Resistance Level | $128.33 | $20.39 |
| Average True Range (ATR) | 2.43 | 0.73 |
| MACD | -0.94 | 0.03 |
| Stochastic Oscillator | 1.17 | 23.89 |
Price Performance
Historical ComparisonAbout ALV Autoliv Inc.
Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.